Cohance Lifesciences Ltd

Cohance Life Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Cohance Lifesciences Ltd

₹ 881 -1.94%
26 Aug - close price
suvenpharm.com BSE: 543064 NSE: COHANCE
About

Hyderabad based CDMO company that offers services to leading global pharmaceutical and fine chemical majors in their NCE development endeavours. From process research & development to late-stage clinical and commercial manufacturing we are committed to provide customers with products fulfilling customer needs and expectations.[1]

Key Points

Market Position
The company has established a strong presence in the contract research and manufacturing services (CRAMS) sector and is one of the top 5 providers of high-end intermediates to innovators in India. [1]

Website BSE NSE
  • Market Cap ₹ 33,698 Cr.
  • Current Price ₹ 881
  • High / Low ₹ 1,360 / 878
  • Stock P/E 95.4
  • Book Value ₹ 91.0
  • Dividend Yield 0.00 %
  • ROCE 31.0 %
  • ROE 23.0 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company is expected to give good quarter
  • Company has a good return on equity (ROE) track record: 3 Years ROE 20.9%
  • Promoter holding has increased by 16.3% over last quarter.
  • Company's working capital requirements have reduced from 93.5 days to 68.9 days

Cons

  • Stock is trading at 9.68 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Promoters have pledged or encumbered 100% of their holding.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 BSE SmallCap Nifty MNC

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
339 278 348 364 344 225 213 253 488 236 284 769 484
184 172 201 187 174 127 144 180 363 135 171 546 379
Operating Profit 155 107 147 177 170 97 69 73 125 101 113 223 104
OPM % 46% 38% 42% 49% 49% 43% 32% 29% 26% 43% 40% 29% 22%
11 10 13 11 10 14 14 17 19 13 16 -8 5
Interest 1 0 1 5 1 0 2 2 10 1 3 7 7
Depreciation 11 11 11 11 11 10 11 17 31 12 15 43 31
Profit before tax 154 106 147 172 168 101 70 71 103 101 111 166 71
Tax % 26% 26% 26% 25% 26% 26% 25% 25% 27% 24% 25% 26% 26%
114 79 109 130 124 75 52 53 75 76 84 123 53
EPS in Rs 4.48 3.10 4.30 5.11 4.88 2.94 2.06 2.09 2.96 3.00 3.29 4.82 1.37
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 5m Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
378 834 1,010 1,320 1,330 1,025 2,504 1,772
206 449 567 738 739 615 1,720 1,231
Operating Profit 172 385 443 582 591 410 784 541
OPM % 45% 46% 44% 44% 44% 40% 31% 31%
1 18 14 188 45 55 49 26
Interest 3 22 12 9 13 7 37 18
Depreciation 12 24 32 39 43 49 147 101
Profit before tax 158 358 414 722 579 409 650 449
Tax % 31% 24% 25% 23% 25% 25% 24%
109 270 309 558 433 305 491 335
EPS in Rs 10.61 12.12 21.92 16.99 11.97 19.29 12.48
Dividend Payout % 0% 24% 16% 23% 35% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 25%
3 Years: 24%
TTM: 50%
Compounded Profit Growth
10 Years: %
5 Years: 14%
3 Years: -3%
TTM: 38%
Stock Price CAGR
10 Years: %
5 Years: 21%
3 Years: 23%
1 Year: -17%
Return on Equity
10 Years: %
5 Years: 26%
3 Years: 21%
Last Year: 23%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 0.00 13 25 25 25 25 25
Reserves 578 770 1,040 1,495 1,724 2,030 2,290
83 186 143 97 70 65 99
123 142 151 187 139 120 174
Total Liabilities 783 1,111 1,359 1,805 1,958 2,241 2,588
271 357 441 534 512 524 686
CWIP 111 102 96 30 165 179 253
Investments 7 276 426 600 710 1,085 1,116
394 376 395 641 571 453 533
Total Assets 783 1,111 1,359 1,805 1,958 2,241 2,588

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
50 359 330 270 493 371 301
-65 -367 -258 -90 -237 -382 -321
26 9 -77 -156 -243 -14 21
Net Cash Flow 11 1 -4 23 13 -25 1

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 142 51 37 65 30 45 35
Inventory Days 556 278 243 259 284 266 69
Days Payable 190 113 100 97 61 50 32
Cash Conversion Cycle 509 217 180 228 253 261 73
Working Capital Days 205 64 56 107 99 112 69
ROCE % 46% 39% 50% 34% 19% 31%

Shareholding Pattern

Numbers in percentages

Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025
60.00% 60.00% 60.00% 60.00% 60.00% 60.00% 50.10% 50.10% 50.10% 50.10% 50.10% 66.41%
7.58% 8.11% 9.47% 9.50% 10.01% 10.14% 9.54% 9.80% 10.70% 10.84% 11.05% 7.23%
10.87% 11.36% 11.43% 10.63% 14.13% 15.94% 17.24% 17.42% 16.95% 16.67% 16.60% 11.40%
0.00% 0.00% 0.00% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
21.56% 20.55% 19.10% 19.88% 15.85% 13.93% 23.11% 22.67% 22.26% 22.37% 22.24% 14.95%
No. of Shareholders 82,57779,41272,88572,16773,71570,05268,93265,77769,33784,21086,32580,910

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls